title: 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
abstract: OBJECTIVE
  The aim of this study is to compare regional cerebral metabolic rate of glucose metabolism and amyloid-β density in patients with Alzheimer disease (AD), mild cognitive impairment (MCI), and healthy elderly subjects.
  
  
  METHODS
  Eighteen patients (including 6 AD, 5 amnestic MCI, and 7 controls) were enrolled at the University Hospital of Tours, France, and submitted to clinical, neuropsychological, and MRI examinations. PET images using F-florbetapir (266 MBq) and F-FDG (185 MBq) were acquired. SUV ratios in specific regions were defined using PMOD3.2 software.
  
  
  RESULTS
  The mean values of F-FDG SUV ratio were significantly lower in frontal, anterior cingulate, and temporal regions in MCI patients than in normal elderly (-15%, -22%, and -11%, respectively). Alzheimer disease patients showed global cerebral metabolic rate of glucose metabolism decrease, especially in parietal and precuneus regions (-15% and -13% compared with healthy control subjects). Only precuneus cortex showed an increased F-florbetapir uptake in AD. There was no other significant regional difference in the amyloid-β density.
  
  
  CONCLUSIONS
  In this study, we observed regional brain metabolic changes between MCI, AD, and controls, whereas only precuneus showed an increased amyloid-β density in AD. F-florbetapir PET analysis needs to be visual and global, whereas F-FDG analysis can be regional.
authors.affiliation: From the *Nuclear Medicine Unit, CHR Orléans, †Hôpital Bretonneau, CHRU Hôpitaux de Tours; ‡INSERM U930 and Université François Rabelais de Tours; §Memory Clinic, CMRR, Hôpital Bretonneau; ‖CIC INSERM 1415; and ¶CIC-IT INSERM, CHRU Hôpitaux de Tours, Tours, France.
authors.forename: Matthieu
authors.initials: M
authors.lastname: Bailly
authors.forename: Maria Joao Santiago
authors.initials: MJ
authors.lastname: Ribeiro
authors.forename: Johny
authors.initials: J
authors.lastname: Vercouillie
authors.forename: Caroline
authors.initials: C
authors.lastname: Hommet
authors.forename: Valérie
authors.initials: V
authors.lastname: Gissot
authors.forename: Vincent
authors.initials: V
authors.lastname: Camus
authors.forename: Denis
authors.initials: D
authors.lastname: Guilloteau
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000814:Aniline Compounds; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism; D016022:Case-Control Studies; D060825:Cognitive Dysfunction / Q000000981:diagnostic imaging*; D005026:Ethylene Glycols; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D016229:Amyloid beta-Peptides; D000814:Aniline Compounds; D005026:Ethylene Glycols; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C545186:florbetapir